Hypoglycemia is the major barrier to good glycemic control in patients with diabetes mellitus. Furthermore, randomized controlled trials have emphasized the grave risks associated with severe ...
MBX Biosciences (MBX) completed the last subject’s last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the company’s long-acting glucagon-like peptide 1 receptor antagonist ...
The tumor was resected with cure of symptoms. A 41-year-old Maltese woman was referred to a specialist center for evaluation of fasting hypoglycemia. The patient reported a 12-month history of ...
Reports of fluoroquinolone-induced hypoglycemia are abundant, but reports of hyperglycemia induced by fluoroquinolones are also available. [15–19] The primary theory of fluoroquinolone ...
It was designed using the Company’s novel, proprietary PEP™ platform to prevent the occurrence of severe hypoglycemia in individuals with PBH so they can lead healthier and more independent lives.